We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+0.73%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$731M
AUM Growth
-$365M
Cap. Flow
-$340M
Cap. Flow %
-46.53%
Top 10 Hldgs %
45.16%
Holding
128
New
24
Increased
37
Reduced
18
Closed
39

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$18.7M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$11.5M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.99M
4
VRNT
Verint Systems
VRNT
+$9.95M
5
STOK icon
Stoke Therapeutics
STOK
+$9.42M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$31.2M
2
NVO
Novo Nordisk
NVO
+$20.9M
3
VTRS icon
Viatris
VTRS
+$13.3M
4
NVS icon
Novartis
NVS
+$9.61M
5
PTCT icon
PTC Therapeutics
PTCT
+$8.3M

Sector Composition

Rank Sector Weight
1 Healthcare 70.2%
2 Technology 11.72%
3 Industrials 2.28%
4 Consumer Discretionary 1.91%
5 Communication Services 0.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRE icon
76
Spyre Therapeutics
SYRE
$8.54B
$1.28M 0.18%
7,488
-31,512
-81% -$5.45M
HSACU
77
DELISTED
Health Sciences Acquisitions Corporation Units
HSACU
$1.05M 0.14%
+100,000
New +$1.04M
ABUS icon
78
Arbutus Biopharma
ABUS
$857M
$1.04M 0.14%
+500,000
New +$1.28M
PHXM
79
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$853K 0.12%
11,904
-96
-0.8% -$7.07K
MRSN
80
DELISTED
Mersana Therapeutics
MRSN
$810K 0.11%
8,000
– –
XFOR icon
81
X4 Pharmaceuticals
XFOR
$375M
$711K 0.1%
+1,580
New +$803K
KZR
82
DELISTED
Kezar Life Sciences
KZR
$534K 0.07%
+6,920
New +$1.08M
VTGN icon
83
VistaGen Therapeutics
VTGN
$9.89M
$489K 0.07%
22,454
-44,948
-67% -$1.19M
CUE icon
84
Cue Biopharma
CUE
$113M
$450K 0.06%
1,667
– –
DK icon
85
Delek US
DK
$4.16B
$338K 0.05%
8,347
-21,810
-72% -$798K
MRNS
86
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$332K 0.05%
+20,000
New +$347K
NICE icon
87
Nice
NICE
$5.79B
$243K 0.03%
1,771
-30,000
-94% -$4.05M
CLRB icon
88
Cellectar Biosciences
CLRB
$20.5M
$191K 0.03%
292
– –
BNTC icon
89
Benitec Biopharma
BNTC
$402M
$30K ﹤0.01%
157
-314
-67% -$127K
ANAB icon
90
AnaptysBio
ANAB
$1.58B
– –
-70,000
Closed -$5.11M
BIIB icon
91
Biogen
BIIB
$30B
– –
-30,000
Closed -$7.09M
BIIB icon
92
PUT
Biogen
BIIB
$30B
– –
-60,000
Closed -$14.2M
CHRS icon
93
Coherus Oncology
CHRS
$217M
– –
-75,600
Closed -$1.03M
CLLS
94
Cellectis
CLLS
$277M
– –
-447,970
Closed -$8.22M
CRVS icon
95
Corvus Pharmaceuticals
CRVS
$1.12B
– –
-83,607
Closed -$336K
CTMX icon
96
CytomX Therapeutics
CTMX
$675M
– –
-183,151
Closed -$1.97M
FBRX icon
97
Forte Biosciences
FBRX
$1.57B
– –
-320
Closed -$1.3M
GILD icon
98
Gilead Sciences
GILD
$162B
– –
-480,000
Closed -$31.2M
GILT icon
99
Gilat Satellite Networks
GILT
$834M
– –
-176,406
Closed -$1.48M
CBIO
100
Crescent Biopharma
CBIO
$537M
– –
-3,110
Closed -$3.88M
2 3
4
5 6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2019 Portfolio in Review

As of Q2 2019, Sphera Funds Management held 128 positions worth $731M, down 33% from $1.1B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sphera Funds Management withdrew a net $340M in Q2 2019, closing 39 positions and reducing 18 holdings. Its most notable exit was Gilead Sciences, an estimated $31.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 55% a quarter earlier, followed by Technology and Industrials.

Against the trend, Sphera Funds Management opened a new position in Regeneron Pharmaceuticals worth $9.39M.

  • Sphera Funds Management's largest Q2 2019 buy was Regeneron Pharmaceuticals: 30,000 shares worth $9.39M.
  • Sphera Funds Management added most to Johnson & Johnson in Q2 2019, an estimated $18.7M increase.
  • Sphera Funds Management's biggest Q2 2019 reduction was Viatris, cutting an estimated $13.3M.
  • Sphera Funds Management fully exited Gilead Sciences in Q2 2019, selling an estimated $31.2M.
  • Sphera Funds Management's ten largest holdings make up 45% of its $731M portfolio in Q2 2019.
  • Sphera Funds Management opened 24 new positions and closed 39 in Q2 2019.
  • Sphera Funds Management's portfolio value fell 33% quarter-over-quarter to $731M.

Based on Sphera Funds Management's 13F filing for Q2 2019, filed 14 Aug 2019.